Treatment strategies for autoimmune encephalitis

@article{Shin2018TreatmentSF,
  title={Treatment strategies for autoimmune encephalitis},
  author={Yong-Won Shin and Soon-Tae Lee and Kyungil Park and Keun-Hwa Jung and Ki-Young Jung and Sang Kun Lee and Kon Chu},
  journal={Therapeutic Advances in Neurological Disorders},
  year={2018},
  volume={11}
}
  • Y. Shin, Soon-Tae Lee, K. Chu
  • Published 16 August 2017
  • Medicine, Biology
  • Therapeutic Advances in Neurological Disorders
Autoimmune encephalitis is one of the most rapidly growing research topics in neurology. Along with discoveries of novel antibodies associated with the disease, clinical experience and outcomes with diverse immunotherapeutic agents in the treatment of autoimmune encephalitis are accumulating. Retrospective observations indicate that early aggressive treatment is associated with better functional outcomes and fewer relapses. Immune response to first-line immunotherapeutic agents (corticosteroids… 

Tables from this paper

Autoimmune encephalitis and immune therapy: lessons from Argentina
TLDR
It is demonstrated the importance of early and aggressive immunosuppressive therapy to achieve a good clinical outcome and a fast recovery without relapses, by reviewing the medical records of Argentine patients with AE treated between 2013 and 2018.
Systematic Review: Syndromes, Early Diagnosis, and Treatment in Autoimmune Encephalitis
TLDR
The aim of this review is to describe the current state of knowledge about autoimmune encephalitis to provide clinicians with a concise, up-to-date overview and to improve the identification of affected patients, treatment strategies, and outcomes in the years to come.
Immunotherapy in Autoantibody-Associated Psychiatric Syndromes in Adults
TLDR
The immunotherapeutic landscape for patients with autoantibody-associated psychiatric syndromes is delineated and it is suggested that in patients with a probable autoimmune-based psychiatric syndrome should be given early corticosteroids, intravenous immunoglobulins, or plasmapheresis as first line immunotherapy.
Use and Safety of Immunotherapeutic Management of N-Methyl-d-Aspartate Receptor Antibody Encephalitis
TLDR
Separate treatment factors are associated with functional outcomes and relapsing disease biology in those with NMDAR antibody encephalitis.
Case Report: Daratumumab in a Patient With Severe Refractory Anti-NMDA Receptor Encephalitis
TLDR
The case of a 20-year-old woman suffering from a severe therapy refractory course of anti-NMDA receptor encephalitis is described, with a successful treatment using the anti-CD38 monoclonal antibody daratumumab.
Management of Autoimmune Encephalitis: An Observational Monocentric Study of 38 Patients
TLDR
This monocentric study compares demographics, diagnostics, treatment options and outcomes with knowledge from literature, and discusses when to stop immunosuppressive therapy since how long treatment should be performed after clinical stabilization or an acute relapse is still a matter of debate.
Autoimmune encephalitis: clinical spectrum and management
TLDR
This work summarises the well-known autoantibody-mediated encephalitis syndromes with neuronal cell-surface antigens and highlights more basic neuroimmunological advances that will inform their future diagnosis and treatments.
International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis
TLDR
These international consensus recommendations for the management of pediatric NMDARE aim to standardize the treatment and provide practical guidance for clinicians, rather than absolute rules.
The use of corticosteroids in autoimmune encephalitis. Basic and clinical considerations
TLDR
AE is a brain inflammation caused by autoantibodies that target proteins, intracellular and extracellular antigens, triggering damage in the CNS, and its treatment is based primarily on immunotherapy, where corticosteroids as immunosuppressive agents play a key role in the treatment along with other agents.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 166 REFERENCES
Rituximab treatment for autoimmune limbic encephalitis in an institutional cohort
TLDR
This study provides Class IV evidence that rituximab improves mRS scores for patients with autoimmune limbic encephalitis who fail first-line therapy, regardless of autoantibody status.
Practical considerations on the use of rituximab in autoimmune neurological disorders
TLDR
The evidence-based effectiveness of rituximab in neurological disorders based on controlled trials and anecdotal reports is reviewed, and the immunobiology of B-cells in autoimmune central nervous system (CNS) and peripheral nervous System (PNS) disorders is addressed.
Tocilizumab in Autoimmune Encephalitis Refractory to Rituximab: An Institutional Cohort Study
TLDR
Tocilizumab might be a good treatment strategy for treating AE refractory to conventional immunotherapies and rituximab, and manifests as early at 1 month after treatment initiation.
Immunoadsorption or plasma exchange in the treatment of autoimmune encephalitis: a pilot study
TLDR
Both IA and PE resulted in moderate to marked clinical improvement, with a low rate of adverse events, and apheresis is well tolerated and effective also as first-line therapy in autoimmune encephalitis, particularly in patients with antibodies targeting neuronal surfaces.
Immune therapy in autoimmune encephalitis: a systematic review
We have reviewed the literature of immune therapy in autoimmune encephalitis associated with antibodies to cell surface antigens including N-methyl-D-aspartate receptor (NMDAR), leucine-rich,
ImmunoglobuliN in the Treatment of Encephalitis (IgNiTE): protocol for a multicentre randomised controlled trial
TLDR
The protocol for the first ever randomised control trial of IVIG treatment for children with all-cause encephalitis is described, with the primary outcome being ‘good recovery’, at 12 months after randomisation.
A clinical approach to diagnosis of autoimmune encephalitis
...
1
2
3
4
5
...